Added to YB: 2024-10-04
Pitch date: 2024-10-03
BMY [bullish]
Bristol-Myers Squibb Company
+3.02%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Market Cap
$105.2B
Pitch Price
$50.87
Price Target
65.00 (+24%)
Dividend
4.80%
EV/EBITDA
7.15
P/E
17.39
EV/Sales
2.90
Sector
Pharmaceuticals
Category
growth
Bristol-Myers Squibb Company - $BMY
BMY: Undervalued at $60, targeting $65. Core portfolio maintenance challenges offset by neuroscience expansion. Cobenfy launch for schizophrenia + KarXT platform for Alzheimer's, psychosis, etc. Competition from Abbvie, Eli Lilly. Upside potential to $80-$100 if KarXT succeeds. Continual review based on clinical trial results.
Read full article (4 min)